*

Hitt og þetta 27. júlí 2006

SOMAXON PHARMACEUTICALS REPORTS POSITIVE RESULTS FROM A PILOT PHASE 2 STUDY OF ORAL NALMEF

Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) announced that oral nalmefene hydrochloride, an opiate antagonist under development by the company, demonstrated positive results in a pilot Phase 2 clinical trial for smoking cessation.

For further information please refer to www.somaxon.com.

BioTie has lisenced the North-American rights of nalmefene to Somaxon Pharmaceuticals.

Turku, 27 July, 2006

Biotie Therapies Corp.

Timo Veromaa President and CEO

For further information, please contact:

Timo Veromaa, President and CEO, Biotie Therapies Corp. tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com www.biotie.com

DISTRIBUTED TO Helsinki Exchanges The main media